| Literature DB >> 33500292 |
Robert James Mash1, Mellisa Presence-Vollenhoven2,3, Adeloye Adeniji2,4, Renaldo Christoffels5,3, Karlien Doubell2,4, Lawson Eksteen2,4, Amee Hendrikse3, Lauren Hutton2,4, Louis Jenkins2,4, Paul Kapp2,4, Annie Lombard2,3, Heleen Marais3, Liezel Rossouw5,3, Katrin Stuve6,3, Abi Ugoagwu5,3, Beverley Williams2,4.
Abstract
OBJECTIVES: To describe the characteristics, clinical management and outcomes of patients with COVID-19 at district hospitals.Entities:
Keywords: COVID-19; accident & emergency medicine; respiratory infections
Year: 2021 PMID: 33500292 PMCID: PMC7839306 DOI: 10.1136/bmjopen-2020-047016
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Characteristics of patients on arrival at the EC
| All | Metro | Rural | P value | |
| Primary care facility | 137 (10.0) | 69 (6.8) | 68 (18.9) | <0.001 |
| Private general practice | 147 (10.7) | 105 (10.3) | 42 (11.7) | |
| Self-referral | 972 (70.6) | 736 (72.4) | 235 (65.5) | |
| Higher hospital | 5 (0.4) | 5 (0.5) | 0 (0.0) | |
| Other | 40 (2.9) | 26 (2.6) | 14 (3.9) | |
| Not known | 75 (5.5) | 75 (7.4) | 0 (0.0) | |
| Sore throat | 332 (24.1) | 186 (18.3) | 146 (40.7) | <0.001 |
| Nasal symptoms | 93 (6.8) | 61 (6.0) | 32 (8.9) | 0.059 |
| Body pains/myalgia | 360 (26.2) | 248 (24.4) | 112 (31.2) | 0.012 |
| Fever | 441 (32.0) | 302 (29.7) | 139 (38.7) | 0.002 |
| Cough | 877 (63.7) | 612 (60.2) | 265 (73.8) | <0.001 |
| Shortness of breath | 717 (52.1) | 545 (53.6) | 172 (47.9) | 0.062 |
| Fatigue | 181 (13.2) | 155 (15.3) | 26 (7.2) | <0.001 |
| Loss smell | 64 (4.7) | 43 (4.2) | 21 (5.8) | 0.211 |
| Loss taste | 49 (3.6) | 29 (2.9) | 20 (5.6) | 0.017 |
| Diarrhoea | 82 (6.0) | 70 (6.9) | 12 (3.3) | 0.015 |
| Headache | 222 (16.1) | 157 (15.5) | 65 (18.1) | 0.240 |
| Other | 298 (21.7) | 250 (24.6) | 47 (13.1) | <0.001 |
| Temperature >37.5°C | 162 (12.4) | 96 (10.0) | 66 (19.0) | <0.001 |
| Respiratory rate >18/min | 650 (50.5) | 505 (52.7) | 145 (43.9) | 0.007 |
| Pulse rate >100/min | 646 (47.9) | 491 (49.3) | 154 (43.8) | 0.013 |
| Systolic BP <90 mm Hg | 31 (2.6) | 28 (3.2) | 3 (1.0) | 0.08 |
| Systolic BP >140 mm Hg | 360 (30.0) | 259 (29.3) | 101 (32.3) | |
| Diastolic BP <60 mm Hg | 101 (8.4) | 87 (9.8) | 14 (4.5) | 0.008 |
| Diastolic BP >90 mm Hg | 217 (18.1) | 152 (17.2) | 65 (20.7) | |
| Oxygen saturation <95% | 557 (41.9) | 439 (44.8) | 118 (33.8) | <0.001 |
| Random blood glucose <4.0 mmol/L | 22 (2.5) | 15 (2.1) | 7 (3.9) | 0.228 |
| Random blood glucose >7.8 mmol/L | 397 (44.3) | 324 (45.4) | 73 (40.3) | |
| Alert | 1264 (91.9) | 921 (90.6) | 342 (95.3) | 0.034 |
| Confused but responds to verbal commands | 82 (6.0) | 69 (6.8) | 13 (3.6) | |
| Unconscious but responds to pain | 10 (0.7) | 7 (0.7) | 3 (0.8) | |
| Unconscious with no response to pain | 6 (0.4) | 5 (0.5) | 1 (0.3) | |
BP, blood pressure; EC, emergency centre.
Comorbidities of patients with COVID-19
| All | Metro | Rural | P value | |
| Overweight/Obesity | 269 (19.5) | 208 (20.5) | 61 (17.0) | 0.153 |
| Type 1 diabetes | 17 (1.2) | 15 (1.5) | 2 (0.6) | 0.175 |
| Type 2 diabetes | 347 (25.2) | 273 (26.9) | 74 (20.6) | 0.019 |
| Hypercholesterolaemia | 83 (6.0) | 77 (7.6) | 6 (1.7) | <0.001 |
| Hypertension | 564 (41.0) | 454 (44.7) | 109 (30.4) | <0.001 |
| Cardiac failure | 58 (4.2) | 51 (5.0) | 7 (1.9) | 0.013 |
| Ischaemic heart disease | 25 (1.8) | 24 (2.4) | 1 (0.3) | 0.011 |
| Asthma | 67 (4.9) | 52 (5.1) | 15 (4.2) | 0.477 |
| COPD | 50 (3.6) | 38 (3.7) | 12 (3.3) | 0.729 |
| Post-TB lung damage | 12 (0.9) | 8 (0.8) | 4 (1.1) | 0.567 |
| HIV | 195 (14.2) | 156 (15.4) | 39 (10.9) | 0.036 |
| Active TB on treatment | 23 (1.7) | 20 (2.0) | 3 (0.8) | 0.150 |
| Previous TB | 49 (3.6) | 40 (3.9) | 9 (2.5) | 0.209 |
| Cancer on treatment | 10 (0.7) | 9 (0.9) | 1 (0.3) | 0.244 |
| Previous cancer | 2 (0.1) | 2 (0.2) | 0 (0.0) | 0.400 |
| Chronic kidney disease | 60 (4.4) | 55 (5.4) | 5 (1.4) | 0.001 |
| None | 450 (32.7) | 276 (27.2) | 174 (48.5) | <0.001 |
| Tobacco smoker | 95/621 (15.3) | 80/490 (16.3) | 15/131 (11.5) | 0.168 |
| Normal HbA1c <7% | 32 (9.2) | 30 (10.8) | 2 (2.9) | 0.002 |
| Controlled HbA1c 7%–8% | 41 (11.8) | 34 (12.2) | 7 (10.1) | |
| Uncontrolled HbA1c >8 and <10% | 68 (19.5) | 56 (20.1) | 12 (17.4) | |
| Very uncontrolled ≥10% | 131 (37.6) | 110 (39.4) | 21 (30.4) | |
| Unknown | 76 (21.8) | 49 (17.6) | 27 (39.1) | |
| Well controlled | 165 (37.0) | 150 (41.6) | 14 (16.7) | <0.001 |
| Uncontrolled | 88 (19.7) | 75 (20.8) | 13 (15.5) | |
| Not known | 193 (43.3) | 136 (37.7) | 57 (67.9) | |
| Well controlled | 23 (31.9) | 21 (51.2) | 2 (6.5) | <0.001 |
| Partly controlled | 10 (13.9) | 6 (14.6) | 4 (12.9) | |
| Uncontrolled | 5 (6.9) | 5 (12.2) | 0 (0.0) | |
| Unknown | 34 (47.2) | 9 (22.0) | 25 (80.6) | |
| Mild | 7 (12.5) | 5 (15.6) | 2 (8.3) | <0.001 |
| Moderate | 11 (19.6) | 9 (28.1) | 2 (8.3) | |
| Severe | 13 (23.2) | 12 (37.5) | 1 (4.2) | |
| Unknown | 25 (44.6) | 6 (18.8) | 19 (79.2) | |
| Well controlled | 96 (53.3) | 79 (57.7) | 17 (39.5) | 0.004 |
| Uncontrolled | 22 (12.2) | 15 (10.9) | 7 (16.3) | |
| Unknown | 43 (23.9) | 25 (18.2) | 18 (41.9) | |
| No ART | 16 (8.9) | 16 (11.7) | 0 (0.0) | |
| New on ART | 3 (1.7) | 2 (1.5) | 1 (2.3) | |
ART, antiretroviral treatment; COPD, chronic obstructive pulmonary disease; HbA1c, haemoglobin A1c; TB, tuberculosis.
Initial assessment and disposition from the emergency centre
| All | Metro | Rural | P value | |
| Triage green | 455 (33.1) | 267 (26.4) | 188 (53.1) | <0.001 |
| Triage yellow | 292 (21.3) | 200 (19.7) | 91 (25.7) | |
| Triage orange | 516 (37.7) | 453 (44.7) | 63 (17.8) | |
| Triage red | 105 (7.7) | 93 (9.2) | 12 (3.4) | |
| Mild COVID | 676 (49.1) | 443 (43.6) | 232 (64.6) | <0.001 |
| Moderate COVID | 252 (18.3) | 191 (18.8) | 61 (17.0) | |
| Severe COVID | 335 (24.3) | 303 (29.8) | 32 (8.9) | |
| Critical COVID | 82 (6.0) | 72 (7.1) | 10 (2.8) | |
| Unknown COVID | 31 (2.3) | 7 (0.7) | 24 (6.7) | |
| Discharged home | 581 (42.2) | 378 (37.2) | 203 (56.5) | <0.001 |
| Transferred to higher level | 85 (6.2) | 66 (6.5) | 19 (5.3) | |
| Transferred to assisted isolation | 12 (0.9) | 2 (0.2) | 10 (2.8) | |
| Transferred to field hospital | 20 (1.5) | 19 (1.9) | 1 (0.3) | |
| Admitted to district hospital | 652 (47.4) | 531 (52.2) | 121 (33.7) | |
| Died | 13 (0.9) | 10 (1.0) | 3 (0.8) | |
| Other | 13 (0.9) | 11 (1.1) | 2 (0.6) | |
Treatment received at the district hospital
| All | Admitted | Metro | Rural | P value | |
| Any form of oxygen | 558 (40.6) | 461 (70.7) | 452 (44.5) | 106 (29.5) | <0.001 |
| Oxygen by nasal prongs 1–4 L/min | 265 (19.3) | 212 (32.5) | 226 (22.2) | 39 (10.9) | <0.001 |
| Oxygen by facemask 6–10 L/min | 240 (17.4) | 212 (32.5) | 207 (20.4) | 33 (9.2) | <0.001 |
| Oxygen with non-rebreather reservoir bag 10–15 L/min | 177 (12.9) | 130 (19.9) | 136 (13.4) | 41 (11.4) | 0.339 |
| Oxygen high flow >15 L/min | 12 (0.9) | 8 (1.2) | 6 (0.6) | 6 (1.7) | 0.058 |
| Intubation and ventilation | 11 (0.8) | 3 (0.5) | 5 (0.5) | 6 (1.7) | 0.031 |
| Proning | 142 (10.3) | 105 (16.1) | 135 (13.3) | 7 (1.9) | <0.001 |
| Enoxaparin sodium any | 583 (42.4) | 503 (77.1) | 504 (49.6) | 79 (22.0) | <0.001 |
| Enoxaparin sodium 40 mg/day | 308 (22.4) | 272 (41.7) | 250 (24.6) | 58 (16.2) | 0.001 |
| Enoxaparin sodium 1 mg/kg daily | 218 (15.8) | 191 (29.3) | 203 (20.0) | 15 (4.2) | <0.001 |
| Enoxaparin sodium 1 mg/kg two times per day | 74 (5.4) | 57 (8.7) | 67 (6.6) | 7 (1.9) | 0.001 |
| Ceftriaxone | 556 (40.4) | 460 (70.6) | 501 (49.3) | 55 (15.3) | <0.001 |
| Azithromycin | 541 (39.3) | 427 (65.5) | 440 (43.3) | 101 (28.1) | <0.001 |
| Co-amoxiclav | 166 (12.1) | 106 (16.3) | 80 (7.9) | 86 (24.0) | <0.001 |
| Any steroid | 253 (18.4) | 183 (28.1) | 196 (19.3) | 57 (15.9) | 0.151 |
| Dexamethasone | 111 (8.1) | 78 (12.0) | 83 (8.2) | 28 (7.8) | 0.825 |
| Hydrocortisone | 15 (1.1) | 12 (1.8) | 13 (1.3) | 2 (0.6) | 0.257 |
| Prednisone | 131 (9.5) | 97 (14.9) | 102 (10.0) | 29 (8.1) | 0.277 |
Clinical outcomes at the district hospitals
| Clinical outcome | Admitted | All | Metro | Rural | Mild | Moderate | Severe | Critical |
| Died | 128 (19.6) | 151 (11.0) | 118 (11.6) | 33 (9.2) | 12 (1.8) | 19 (7.5) | 73 (21.8) | 47 (57.3) |
| Discharged home | 324 (49.7) | 831 (60.4) | 577 (56.8) | 253 (70.5) | 525 (77.7) | 147 (58.3) | 130 (38.8) | 7 (8.5) |
| Transferred tertiary hospital | 57 (8.7) | 118 (8.6) | 115 (11.3) | 3 (0.8) | 20 (3.0) | 23 (9.1) | 55 (16.4) | 20 (24.4) |
| Transferred assisted isolation | 30 (4.6) | 47 (3.4) | 20 (2.0) | 27 (7.5) | 26 (3.8) | 11 (4.4) | 3 (0.9) | 0 (0.0) |
| Transferred field hospital | 88 (13.5) | 105 (7.6) | 104 (10.2) | 1 (0.3) | 1.3 (1.9) | 28 (11.1) | 55 (16.4) | 7 (8.5) |
Risk factors for death from COVID-19
| Variable | Unadjusted OR | P value |
| Cancer on treatment | 12.63 (3.5 to 42.3) | <0.001 |
| Chronic kidney disease | 10.65 (6.21 to 18.28) | <0.001 |
| Cancer previous | 8.16 (0.51 to 131.14) | 0.138 |
| Cardiac failure | 5.63 (3.21 to 9.87) | <0.001 |
| Post-TB SLD | 4.14 (1.23 to 13.9) | 0.022 |
| Hypertension | 3.95 (2.73 to 5.70) | <0.001 |
| Type 2 diabetes | 3.1 (2.2 to 4.3) | <0.001 |
| TB on treatment | 2.94 (1.14 to 7.57) | 0.026 |
| Ischaemic heart disease | 2.06 (0.76 to 5.58) | 0.154 |
| Hypercholesterolaemia | 1.88 (1.04 to 3.37) | 0.035 |
| TB previous | 1.88 (0.89 to 3.95) | 0.097 |
| Overweight/Obese | 1.69 (1.15 to 2.49) | 0.007 |
| HIV | 1.67 (1.09 to 2.56) | 0.019 |
| Male sex | 1.63 (1.16 to 2.30) | 0.005 |
| COPD | 1.34 (0.59 to 3.03) | 0.487 |
| Asthma | 1.11 (0.52 to 2.36) | 0.795 |
| Type 1 diabetes | 1.08 (0.24 to 4.78) | 0.916 |
| Increasing age | 1.06 (1.05 to 1.07) | <0.001 |
| Turnaround time | 1.02 (0.99 to 1.06) | 0.216 |
| Tobacco smoking | 1.01 (0.46 to 2.21) | 0.986 |
| Length of admission | 0.97 (0.93 to 1.02) | 0.219 |
| Rural versus metro services | 0.77 (0.51 to 1.16) | 0.208 |
| No comorbidities | 0.17 (0.09 to 0.30) | <0.001 |
| Cancer on treatment | 7.45 (1.87 to 29.89) | 0.004 |
| Chronic kidney disease | 5.16 (2.82 to 9.43) | <0.001 |
| HIV | 3.41 (2.06 to 5.65) | <0.001 |
| Cardiac failure | 2.85 (1.52 to 5.35) | 0.001 |
| Male sex | 2.02 (1.37 to 2.98) | <0.001 |
| Type 2 diabetes | 1.84 (1.24 to 2.73) | 0.002 |
| Overweight/Obese | 1.58 (1.02 to 2.46) | 0.04 |
| Increasing age | 1.06 (1.04 to 1.07) | <0.001 |
COPD, chronic obstructive pulmonary disease; SLD, structural lung damage; TB, tuberculosis.